$BAX

Baxter and B. Braun recalled IV saline bags due to fiberglass and rust particles. Baxter recalled sodium chloride, sodium citrate, and dextrose lots, while B. Braun recalled sodium chloride. No injuries reported, but particles pose serious risks if they enter the bloodstream. Baxter's North Cove plant supplies 60% of U.S. IV fluids, raising concerns about potential shortages. The FDA has not yet classified these recalls.

Baxter International Inc. (BAX) raised its 2026 outlook despite margin pressure, citing strong Q2 growth. The company continues to work with regulators and faces potential customer uncertainty. Becton, Dickinson and Company (BDX) and ICU Medical, Inc. (ICUI) also compete in the infusion technology market. BAX has a Zacks Rank #3 (Hold), with a Value Score of B, Growth Score of B, and VGM Score of B, but a Momentum Score of C.

Baxter International recalled two lots of 0.9% Sodium Chloride injection and one lot of Anticoagulant Sodium Citrate Solution due to potential fiberglass particles, according to the FDA. The recalls were issued on Aug. 25 and 26, with distribution dates in July. Baxter stated no adverse events have been reported as of Sept. 3, 2026, and they are working with the FDA.

Baxter International (BAX) appointed John Rogers as CFO, with CEO Andrew Hider temporarily assuming CFO duties. Rogers brings cross-industry experience, potentially influencing capital allocation and reporting. Baxter aims for $12.4B revenue and $788.3M earnings by 2029, requiring 2.8% yearly revenue growth. The company recently launched a $600M tender offer for longer-dated notes, amending its credit agreement. Investors focus on margin stabilization and leverage.

Baxter International recalled two lots of 0.9% sodium chloride injections due to potential fiberglass contamination. The affected products are in 500ml Viaflex containers with lot numbers Y495523 and Y495523A, distributed to 14 U.S. states. No injuries or illnesses have been reported as of August 25, according to the company.

Baxter International Inc. has appointed John Rogers as Chief Financial Officer, effective October 1, 2026. Rogers brings extensive experience from roles at Smith+Nephew, WPP, and Sainsbury's. He will focus on stabilizing the business and improving execution. Baxter is a global healthcare and medical technology company.

The FDA issued Class I recalls for certain convenience kits by Medline and Medical Action, and for Astral ventilators by ResMed, due to safety concerns. Baxter voluntarily recalled a specific lot of IV solution due to particulate contamination. The recalls may impact the companies' operations and financial performance.

Baxter International recalled two lots of 0.9% Sodium Chloride Injection IV saline due to fibreglass contamination, posing risks of blood clots and death. The recall affects 14 US states and was announced on 25 August 2026. The FDA classified it as a voluntary recall, and Baxter is contacting affected customers for returns.

Baxter International recalled two lots of 0.9% sodium chloride injections due to potential fiberglass contamination. The solution is used in hemodialysis and was distributed to 14 U.S. states. No injuries or illnesses have been reported, according to the company.

Baxter International is recalling one lot of 70% Dextrose Injection due to stainless steel particles found in the solution. The affected lot, Y495066, was distributed to healthcare providers in select states, including Alabama, Georgia, and Tennessee. The company has not reported any adverse events. Patients using parenteral nutrition should contact their compounding pharmacy for guidance. This is the third IV product recall in recent weeks, according to the FDA.